Mr. Hugh MacNaught reports

VENTRIPOINT ISSUES SHARES FOR PAYMENT OF DEBENTURE INTEREST

Ventripoint Diagnostics Ltd. will satisfy debenture interest payment obligation with the issuance of common shares, subject to TSX Venture Exchange approval. The corporation will issue an aggregate of up to 83,864 common shares for the payment of an aggregate of $9,225.20 of interest on certain outstanding convertible debentures issued by the corporation on June 28, 2024. The convertible debentures bear interest at the rate of 10 per cent per annum, payable every six months. The shares will be issued at a deemed price of 11 cents, subject to the approval of TSX-V and are subject to a hold period of four months and one day. The issuance of the shares will not create a control person of the corporation.

Ventripoint also announces it has received TSX-V approval to issue an aggregate of 32,769 common shares to settle an aggregate of $3,276 of interest in respect of convertible debentures issued on May 10, 2024. The corporation had previously announced its intention to issue an aggregate of 112,210 shares to settle an aggregate of $11,221 of interest owing in respect of the May 10, 2024, convertible debentures (see Dec. 9, 2024, press release).

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.